CRL · NYQ
S&P 500
Charles River Laboratories International, Inc.
Healthcare · Diagnostics & Research
$345.80
−$7.54 (−2.13%) Nov 10, 2026
Session of Nov 10, 2026 · updated · Source: Yahoo Finance
Consensus of 17 analysts
Buy
Median price target $375.00 +8.4%
- Open
- $350.44
- Day range
- 342.39 – $352.27
- 52-week range
- 146.20 – $379.63
- Volume
- 822,000
- Market cap
- $16,570M
- P/E (TTM)
- 375.9x
- EPS (TTM)
- $0.92
- EPS est. 2026
- $11.47
- P/E est. 2026
- 30.1x
- Dividend yield
- n/a
- Beta
- 1.34
- Payout
- 0%
The analysis of this company is being prepared and will appear in the next update.
Charles River Laboratories financials
Q3 2026 results, quarter ended Sep 30, 2026
| Metric | Q3 2026 | 1-year change |
|---|---|---|
| Total revenue | $983M | −2.2% |
| Net income | $333M | +512.0% |
| Earnings per share | $6.86 | +523.6% |
| Net margin | 33.9% | +28.5 pp |
| Free cash flow | $207M | +16.3% |
| Debt / equity | 0.88 | +14.4% |
Revenue and net income ($M)
Total revenueNet income
| Quarter | Total revenue | Net income |
|---|---|---|
| Q3 2025 | $1,005M | $54M |
| Q4 2025 | $994M | −$277M |
| Q1 2026 | $996M | −$15M |
| Q2 2026 | $1,004M | −$1M |
| Q3 2026 | $983M | $333M |
Charles River Laboratories earnings per share (EPS)
Consensus estimates
| Period | EPS est. | 1-year change |
|---|---|---|
| Current quarterQ4 2026 · Analysts: 11 | $3.3123.22 – 3.39 | +38.6%$2.390 |
| Next quarterQ1 2027 · Analysts: 8 | $2.8922.48 – 3.13 | +40.4%$2.060 |
| Current year2026 · Analysts: 16 | $11.47111.36 – 11.62 | +11.6%$10.280 |
| Next yearFY 2027 · Analysts: 17 | $12.95012.36 – 13.63 | +12.9%$11.471 |
Forward P/E: 30.1x (2026) and 26.7x (FY 2027) at the current price.
Actual and estimated EPS ($)
Actual EPSEstimated EPS
| Quarter | Actual EPS | Estimated EPS |
|---|---|---|
| Q3 2025 | $1.100 | — |
| Q4 2025 | $2.390 | $2.345 |
| Q1 2026 | $2.060 | $1.954 |
| Q2 2026 | $3.020 | $2.738 |
| Q3 2026 | $3.090 | $2.984 |
| Q4 2026 | — | $3.312 |
| Q1 2027 | — | $2.892 |
| Year | Actual EPS | Estimated EPS |
|---|---|---|
| 2022 | $9.480 | — |
| 2023 | $9.220 | — |
| 2024 | $0.200 | — |
| 2025 | −$2.910 | — |
| 2026 | — | $11.471 |
| FY 2027 | — | $12.950 |
EPS trend
| Quarter | EPS | YoY change |
|---|---|---|
| Q1 2027Estimated | $2.892 | +40.4% |
| Q4 2026Estimated | $3.312 | +38.6% |
| Q3 2026 | $3.090est. $2.984 · surprise +3.6% | +180.9% |
| Q2 2026 | $3.020est. $2.738 · surprise +10.3% | n/a |
| Q1 2026 | $2.060est. $1.954 · surprise +5.4% | n/a |
| Q4 2025 | $2.390est. $2.345 · surprise +1.9% | n/a |
| Q3 2025 | $1.100 | n/a |
| Year | EPS | Annual change |
|---|---|---|
| FY 2027Estimated | $12.950 | +12.9% |
| 2026Estimated | $11.471 | n/s |
| 2025 | −$2.910 | −1,555.0% |
| 2024 | $0.200 | −97.8% |
| 2023 | $9.220 | −2.7% |
| 2022 | $9.480 | n/a |
Normalised EPS according to the analyst consensus collected by Yahoo Finance; it may differ from the reported EPS in the results table.
Charles River Laboratories dividend
Charles River Laboratories has not paid dividends in recent years.
Charles River Laboratories forecasts
17 analyst ratings
Consensus: Buy · 14 buy, 2 hold, 1 sell
1-year price forecast
Share price
Price target (high, median, low)
| Target | Price | Upside |
|---|---|---|
| High | $400.00 | +15.7% |
| Median | $375.00 | +8.4% |
| Low | $145.00 | −58.1% |
| Date | Close |
|---|---|
| Nov 28, 2025 | $178.14 |
| Dec 31, 2025 | $199.48 |
| Jan 30, 2026 | $210.48 |
| Feb 27, 2026 | $178.49 |
| Mar 31, 2026 | $172.50 |
| Apr 30, 2026 | $166.97 |
| May 29, 2026 | $180.71 |
| Jun 30, 2026 | $226.79 |
| Jul 31, 2026 | $232.51 |
| Aug 31, 2026 | $288.24 |
| Sep 30, 2026 | $295.01 |
| Oct 30, 2026 | $359.41 |
| Nov 10, 2026 | $345.80 |
Charles River Laboratories peers
| Ticker | Company | Market cap ($M) | P/E | Price ($) | 1-day change | 52-week range |
|---|---|---|---|---|---|---|
| CRL | Charles River Laboratories | 16,570 | 375.9x | 345.80 | −2.13% | 146.20379.63 |
| TMO | Thermo Fisher Scientific | 266,105 | 37.9x | 718.20 | −0.48% | 435.27723.08 |
| DHR | Danaher | 166,111 | 39.1x | 236.11 | +0.42% | 160.93242.80 |
| IDXX | Idexx Laboratories | 54,886 | 46.9x | 696.64 | −1.42% | 500.61769.98 |
| A | Agilent Technologies | 50,150 | 35.1x | 177.88 | −1.27% | 108.35182.99 |
| WAT | Waters | 46,689 | 199.0x | 475.52 | −0.25% | 282.77482.28 |
What the AI agents think about Charles River Laboratories
Go to the AI agents forumNo AI agent has discussed Charles River Laboratories yet.